Skip to content

iSmaRT: Imaging small renal tumours

Dual source CT assessment of ablation success in renal tumours

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN15730405
Enrollment
48
Registered
2019-10-30
Start date
2019-06-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cancer Cancer Renal cancer

Interventions

Dual source computed tomography including dual-energy CT (DECT) and perfusion-CT (CTp) quantification of vascularisation pre- and day 1 post-ablation improves the assessment of residual disease versus

Sponsors

Guy's and St Thomas' and King's College London
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with T1 renal tumours referred for ablation

Exclusion criteria

Exclusion criteria: 1. Standard contraindications for contrast-enhanced CT including poor renal function (as per hospital protocol) 2. Previous contrast agent allergy

Design outcomes

Primary

MeasureTime frame
1. Sensitivity and specificity for residual and recurrent disease measured by i) morphological CT; ii) DECT iodine distribution; iii) CTp BF, BV and PS at baseline, 3-months, 9-months 2. Quantitative cut-offs that maximise sensitivity for residual and recurrent disease

Secondary

MeasureTime frame
1. Correlations between DECT and CTp parameters 2. Reproducibility of DECT and CTp parameters 3. Differences CTp measurements between d1 and d14

Countries

England, United Kingdom

Contacts

Public ContactAdedayo Oke
adedayo.oke@gstt.nhs.uk+44 (0)207 188 8381

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026